Cough syrup contaminated with DEG has caused ARI and the death of many children in The Gambia.

Published Date: 06 Mar 2023

USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...

Read Full News

Todays Updates


Psychotropics Linked to Increased BMI, CVD Risk


Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL


Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma


In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer


A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival


In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival


A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets


In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

Todays Updates


Psychotropics Linked to Increased BMI, CVD Risk


Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL


Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma


In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer


A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival


In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival


A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets


In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

2.

Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.

3.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

4.

Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers

5.

Can Oncotype Predict Recurrence Risk in Older BC Patients?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot